Wedbush analyst Robert Driscoll raised the firm’s price target on Cullinan Therapeutics (CGEM) to $34 from $25 and keeps an Outperform rating on the shares. The firm notes the company presented initial clinical data for FLT3 x CD3 bispecific CLN-049 in patients with relapsed or refractory acute myeloid leukemia. Cullinan noted that all but one CRS events were Grade 1/2, and most occurred at step up dose, with no discontinuations reported.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Buy Rating for Cullinan Management Driven by Promising CLN-049 Clinical Data and Strategic Development Plan
- Promising Outlook for Cullinan Management: Buy Rating Backed by Strong Therapeutic Developments and Financial Position
- Optimistic Buy Rating for Cullinan Management Driven by Promising CLN-049 Therapy Results
- Cullinan Therapeutics Presents Promising CLN-049 Data
- Cullinan Therapeutics shares updated clinical data from Phase 1 study of CLN-049